MK-3120

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for MK-3120, covering 2026-02-19 to 2026-04-23. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) [Phase 1, Phase 2]